Trials / Completed
CompletedNCT01588353
Collagenase Option for Reduction of Dupuytren's Contracture in Japan
Phase III Study of AK160 in Patients With Dupuytren's Contracture
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Asahi Kasei Therapeutics Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Collagenase Clostridium Histolyticum | AK160 (Collagenase Clostridium Histolyticum) 0.58 mg |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2012-04-30
- Last updated
- 2017-03-21
- Results posted
- 2017-02-14
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01588353. Inclusion in this directory is not an endorsement.